ALLK - Allakos Inc Stock Price, Fair Value and News

$0.33

Market Closed as of 15 May 2025, 04:00 pm ET

ALLK Stock Valuation Analysis

Valuation

Max Portfolio %

ALLK Price Action

ALLK RSI Chart

ALLK Stock Valuation Analysis

Valuation

Max Portfolio %

ALLK Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALLK Fundamentals

ALLK Earnings

ALLK Profitability

ALLK Investor Care

Revenue & Growth

How Allakos Inc generates revenue and covers its expenses, based on the latest reported earnings.

About Allakos Inc

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

CEO	Dr. Robert Alexander Ph.D.
WEBSITE	allakos.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	123